02269 WUXI BIO
- 13.960
- -0.600-4.12%
WUXI BIO News
Pharmaceutical Biotech Releases 2023 ESG Report Highlights Strong Commitment to Sustainable Development
The company keeps its promises, takes social responsibility, and works with customers around the world to create long-term value for all stakeholders. The company has made significant progress on climate change, reducing the intensity of Scope 1 and Scope 2 greenhouse gas emissions by 29% compared to the 2020 base year. The company achieved the water saving target of reducing water density by 18% by 2025 ahead of schedule, and further upgraded the target to 30%. The company has more than 12,000 employees from 56 countries around the world, with women accounting for 53% of employees in science, technology, engineering and mathematics (STEM) positions. The company gained mainstream
藥明生物：二零二三年度報告
Changes in Hong Kong stocks | CRO concept stocks continue to rebound, the downstream demand side needs to improve, and domestic CXO companies still have a competitive advantage
CRO concept stocks continued to rebound. As of press release, Viva Biotech (01873) rose 8.93% to HK$0.61; Kingsley Biotech (01548) rose 8.35% to HK$11.94; Kanglong Chemical (03759) rose 5.91% to HK$10.04; and Pharmaceutical Biotech (02269) rose 5.79% to HK$14.26.
Trending Industry Today: TIGERMED Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
April 26th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending higher today with 8 constituents up and TIGERMED leading Gains.$TIGERMED(03
Changes in Hong Kong stocks | Tiger Pharmaceuticals (03347) rose more than 8% to lead CRO concept stocks, reports say the national level is expected to introduce an action plan for the biological manufacturing industry in the near future
CRO concept stocks increased their gains in the afternoon. As of press release, Tiger Pharmaceuticals (03347) rose 8.39% to HK$33.6; Kanglong Chemical (03759) rose 7.16% to HK$9.43; Pharmaceutical Biotech (02269) rose 6.75% to HK$13.6; and Pharmaceuticals (02359) rose 4.74% to HK$35.35.
On April 23, Yao Ming Biotech spent HK$24.884,200 to buy back 1.905 million shares
Pharmaceutical Biotech (02269) announced that on April 23, 2024, the company spent HK$24.884,200 to repurchase 1.905 million shares at a repurchase price of HK$12.92-13.32 per share.
Pharmaceutical Biotech (02269) spent HK$248.842 million to buy back 1.905 million shares on April 23
Yao Ming Biotech (02269) announced that on April 23, 2024, the company spent 24.8842 million...
On April 22, Yao Ming Biotech spent HK$1991215 million to buy back 1.55 million shares
Pharmaceutical Biotech (02269) announced that on April 22, 2024, it spent HK$1991215 million to repurchase 1.55 million shares.
Pharmaceutical Biotech (02269) spent HK$19912,150 to buy back 1.55 million shares on April 22
Pharmaceutical Biotech (02269) announced that on April 22, 2024, it cost HK$19912,150 to repurchase 15...
Pharmaceutical Biotech (02269.HK) spent HK$1992 million to buy back 1.57 million shares on April 19
Gelonghui, April 19 | Pharmaceutical Biotech (02269.HK) announced that it spent HK$19.92 million to buy back 1.57 million shares on April 19.
Trending Industry Today: GENSCRIPT BIO Leads Losses In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
April 19th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending lower today with 9 constituents down and GENSCRIPT BIO leading Losses.$GENS
On April 16, Yao Ming Biotech spent HK$198932 million to buy back 1.51 million shares
Pharmaceutical Biotech (02269) announced that on April 16, 2024, the company spent HK$19893,200 to repurchase 1.51 million shares at a repurchase price of HK$12.9-13.42 per share.
Pharmaceutical Biotech (02269.HK) spent HK$19.89 million to buy back 1.51 million shares on April 16
Gelonghui, April 16, 丨 Pharmaceutical Biotech (02269.HK) announced that it spent HK$19.89 million to buy back 1.51 million shares on April 16.
Pharmaceutical Biotech (02269) spent HK$198932 million to buy back 1.51 million shares on April 16
Yao Ming Biotech (02269) announced that on April 16, 2024, the company spent 198932 million...
On April 11, Yao Ming Biotech spent HK$19.02 million to buy back 1,415,000 shares
Pharmaceutical Biotech (02269) announced that on April 11, 2024, the company spent HK$19.02 million to repurchase 1,415,000 shares at a repurchase price of HK$13.98-14.16 per share.
Pharmaceutical Biotech (02269.HK) spent HK$19.902 million to buy back 1,415,000 shares on April 11
Gelonghui, April 11 | Pharmaceutical Biotech (02269.HK) announced that on April 11, it spent HK$19.02 million to repurchase 1,415,000 shares.
Changes in Hong Kong stocks | Tiger Pharmaceuticals (03347) rose more than 9%, leading the CRO concept pharmaceutical industry's transformation to innovative drugs and a gradual recovery in biomedical investment and financing
The Zhitong Finance App learned that CRO concept stocks rose collectively. As of press release, Tiger Pharmaceuticals (03347) rose 8.8% to HK$30.3; Zhaoyan Pharmaceutical (06127) rose 6.43% to HK$8.77; Pharmaceutical Biotech (02269) rose 6.59% to HK$14.24; Zhaoyan Pharmaceutical (06127) rose 6.43% to HK$8.77; Pharmaceuticals (02359) rose 3.56% to HK$36.4. Dongwu Securities pointed out that the global CRO market is expanding steadily. Among them, the growth rate of the Chinese CRO market is higher than that of the world, while the clinical CRO market
Pharmaceutical Biotech (02269.HK) spent HK$19.89 million to buy back 1.485,000 shares on April 5
Gelonghui, April 5 | Pharmaceutical Biotech (02269.HK) announced that it spent HK$19.89 million to buy back 1.485 million shares on April 5.
[Broker Focus] CITIC Construction Investment maintains Pharmaceutical Biotech (02269) “buy” rating, indicating that the company's industry recognition continues to increase
Jinwu Financial News | CITIC Construction Investment Research Report shows that in 2023, Yao Ming Biotech (02269) achieved revenue of 17 billion yuan, an increase of 11.6% over the previous year, and a 38% increase in routine business. The number of new projects signed throughout the year reached 132, and the number of commercialized projects reached 24. Global biotech financing has been recovering since 23Q4, and this trend can still be seen. Looking ahead to 2024, the company expects the R&D side to continue to grow steadily, the number of PPQ projects will continue to increase, the Irish base is progressing smoothly and is expected to achieve break-even, and overseas production capacity will continue to expand. Considering the pace of newly signed projects in 23 years and the pace of company adjustments, it is estimated
Pharmaceutical Biotech (02269.HK) gains 3.406 million shares from J.P. Morgan
Gelonghui, April 5 | According to the latest equity disclosure data on the Stock Exchange, on March 27, 2024, Pharmaceutical Biotech (02269.HK) obtained JPMorgan Chase & Co. to increase its holding of 3.406 million shares at an average price of HK$13.6846 per share, involving approximately HK$46.61 million. After the increase in holdings, JPMorgan Chase & Co.'s latest number of open positions was 213,733,454 shares, and the holding ratio increased from 4.93% to 5.01%.
Analysis
Price Target
No Data
